Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Ginkgo Bioworks Holdings, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Other Events  Interactive Data
08/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Unaudited Pro Forma Condensed Combined Statement of Operations of Ginkgo Bioworks Holdings, Inc. for the year ended December 31, 2022",
"Unaudited Pro Forma Condensed Combined Statement of Operations of Ginkgo Bioworks Holdings, Inc. for the year ended December 31, 2022"
08/09/2023 8-K Quarterly results
Docs: "Ginkgo Bioworks Reports Second Quarter 2023 Financial Results Ginkgo added 21 new Cell Programs to the Foundry platform in Q2 2023 Highlighted continued success selling into large established biotech R&D organizations with recently expanded relationships with Sumitomo, Novo Nordisk, and Merck Ginkgo ended Q2 2023 with approximately $1.1 billion in cash and cash equivalents, providing a strong multi-year runway as Ginkgo continues to drive towards profitability BOSTON, MA – August 9, 2023 – Ginkgo Bioworks Holdings, Inc. , which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2023. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial..."
05/05/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/01/2023 8-K Quarterly results
Docs: "Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results $478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance 59 new Cell Programs added in 2022, representing 90% growth over 2021 and toward the high end of guidance Year end cash balance of over $1.3 billion provides meaningful multi-year runway as we drive towards profitability"
01/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Unaudited Consolidated Interim Financial Statements for Zymergen Inc. as of and for the quarterly period ended September 30, 2022",
"Unaudited Pro Forma Condensed Combined Balance Sheet as of September 30, 2022 and the Unaudited Pro Forma Condensed Combined Statements of Operations for the nine months ended September 30, 2022 and the year ended December 31, 2021"
01/11/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review Expects to meet 2022 guidance ranges for Total revenue and new Cell Programs Year end cash balance of approximately $1.3 billion provides ample liquidity and puts Ginkgo in a position of strength to continue to build its leadership position despite a challenging macroenvironment Strong growth among biopharma customers as Ginkgo has scaled its mammalian cell engineering capabilities, including recently opening Bioworks7, which is fully dedicated to mammalian cell engineering workflows Management to highlight updates today at the 41st Annual J.P. Morgan Healthcare Conference at 11:15 a.m. PT BOSTON, MA – January 11, 2023 –"
11/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and between the Company and BTIG, LLC",
"Opinion of Ropes & Gray LLP",
"Information relating to Part II, Item 14 “Other Expenses of Issuance and Distribution” of the Registration Statement"
10/19/2022 8-K Quarterly results
10/04/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Excerpts from the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, reflecting revisions to Part II, Item 7 and Part II, Item 8 thereof",
"Consent of Ernst & Young, LLP, Independent Registered Public Accounting Firm",
"Excerpts from the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, reflecting revisions to Part II, Item 7 and Part II, Item 8 thereof"
08/15/2022 8-K Quarterly results
Docs: "Ginkgo Bioworks Reports Second Quarter 2022 Financial Results $145 million of Total revenue in Q2 2022, representing 231% growth over Q2 2021 13 new Cell Programs added in Q2 2022, representing 86% growth over Q2 2021 Pending acquisitions of Zymergen and Bayer's West Sacramento agricultural biologicals capabilities expected to enable new growth opportunities in the coming years Approximately $1.4 billion cash balance provides continued multi-year runway as Ginkgo drives towards profitability"
08/04/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Ginkgo Bioworks Appoints Kathy Hopinkah Hannan to its Board of Directors BOSTON, MA — August 4, 2022 — Ginkgo Bioworks , the leading horizontal platform for cell programming, today announced that Kathy Hopinkah Hannan, PhD, CPA has joined its Board of Directors, effective August 2, 2022. Dr. Hannan brings over thirty years of experience as a senior C-Suite executive, corporate advisor, independent board director and strategist leading significant operations and high priority initiatives. “As a pioneer in synthetic biology, Ginkgo Bioworks is undertaking critical work to make biology easier to engineer and to enable a more sustainable future,” said Dr. Hannan. “I am honored to join Ginkgo’s Board at such a significant time in the company’s history, and look forward to w..."
07/25/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement and Plan of Merger, by and among Ginkgo Bioworks Holdings, Inc., Pepper Merger Subsidiary Inc. and Zymergen Inc",
"Voting Agreement, entered into by SVF Excalibur (Cayman) Limited",
"Voting Agreement, entered into by Data Collective II, L.P. and certain of its affiliates",
"Voting Agreement, entered into by True Ventures IV, L.P. and certain of its affiliates",
"Ginkgo to Acquire Zymergen"
07/25/2022 8-K Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits  Interac...
Docs: "Ginkgo and Bayer Sign Definitive Agreement to Build Agricultural Biologicals R&D Platform Capabilities"
06/13/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/16/2022 8-K Quarterly results
03/28/2022 8-K Quarterly results
Docs: "Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results $314 million of Total revenue in 2021, representing an increase of 309% over 2020 31 new Cell Programs added in 2021, representing 72% growth over 2020 Over $1.5 billion cash balance, providing meaningful multi-year runway as we drive towards profitability BOSTON, MA -- March 28, 2022 -- Ginkgo Bioworks Holdings, Inc. , the leading horizontal platform for cell programming, today announced its results for the fourth quarter and year ended December 31, 2021. The update, including a webcast slide presentation with additional details on the fourth quarter and supplemental financial information, will be available at investors.ginkgobioworks.com. “The current market environment provides both challenges and opportu..."
01/12/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Ginkgo Bioworks Provides Preliminary Unaudited 2021 Revenue Highlights and Business Review Expects to meet or exceed 2021 performance targets for new cell programs, Foundry revenue, and Biosecurity revenue Management to highlight updates today at the 40th Annual J.P. Morgan Healthcare Conference at 3:45pm ET BOSTON, MA – January 12, 2022 –"
11/24/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Audited consolidated financial statements of the Company as of and for the years ended December 31, 2020 and 2019",
"Consent of Independent Registered Public Accounting Firm",
"Audited consolidated financial statements of the Company as of and for the years ended December 31, 2020 and 2019"
11/15/2021 8-K Quarterly results
Docs: "Ginkgo Bioworks Reports Third Quarter 2021 Results"
09/14/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/14/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds Soaring Eagle Shareholder Approval Obtained, Closing Scheduled for September 16, 2021 Ginkgo Set to Begin Trading under NYSE: DNA on September 17, 2021"
09/08/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Soaring Eagle Announces Achievement of Quorum to Pass Proposed Business Combination with Ginkgo, Proxies Received Indicate Overwhelming Support for All Proposals • Extraordinary General Meeting to Be Held on September 14, 2021; Closing of Business Combination Expected to Occur on September 16, 2021 • Shares of the Combined Company Expected to Begin Trading on NYSE under the ticker “DNA” on September 17, 2021 NEW YORK, N.Y.— September 8, 2021—Soaring Eagle Acquisition Corp. announced today that it had achieved a quorum for the extraordinary general meeting of the Company's shareholders to be held on September 14, 2021 in connection with its business combination with Ginkgo Bioworks, Inc. and that the shareholders who have submitted proxies to date on the proposals included in the Company's..."
09/01/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Soaring Eagle Announces Transfer of Listing to NYSE in Connection with its Proposed Business Combination with Ginkgo"
05/13/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Unaudited Revised Balance Sheet as of February 26, 2021"
05/11/2021 8-K Acquisition/merger/asset purchase announced
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : May 11, 2021 SOARING EAGLE ACQUISITION CORP. Cayman Islands 001-40097 N/A 955 Fifth Avenue 10075 Registrant's telephone number, including area code: 209-7280 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communic...",
"Merger Agreement, by and among Soaring Eagle Acquisition Corp., SRNG Merger Sub Inc. and Ginkgo Bioworks, Inc.†",
"Form of Subscription Agreement",
"Form of Amended and Restated Registration Rights Agreement",
"Company Stockholder Support Agreement, by and among Soaring Eagle Acquisition Corp., SRNG Merger Sub Inc. and certain Supporting Stockholders of Ginkgo Bioworks, Inc",
"Sponsor Support Agreement, by and among Eagle Equity Partners III, LLC, Ginkgo Bioworks, Inc., Soaring Eagle Acquisition Corp. and certain of its shareholders",
"Ginkgo Bioworks to Become a Public Company and Expand its Leading Platform for Cell Programming",
"Investor Presentation, dated May 2021",
"Summary Risk Factors"
04/15/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : April 15, 2021 SOARING EAGLE ACQUISITION CORP. Cayman Islands 001-40097 N/A 955 Fifth Avenue 10075 Registrant's telephone number, including area code: 209-7280 Not Applicable Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Units, each consisting of one Class A ordinary share and one-fifth of one redeemable warrant SRNGU The Nasdaq Stock Market LLC Class A ordinary share, par value $0.0001 per share SRNG The Nasdaq Stock Market LLC Redeemable warrants, each whole warrant exercisable for one Class A ordinary share, each at an ex...",
"Soaring Eagle Acquisition Corp., Led by Eagle Equity Partners' Harry Sloan, Jeff Sagansky and Eli Baker Announces Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about April 19, 2021 April 15, 2021 — Soaring Eagle Acquisition Corp. , the seventh public acquisition vehicle led by Eagle Equity Partners' Harry Sloan, Jeff Sagansky and Eli Baker today announced that holders of the units sold in the Company's initial public offering of 172,500,000 units completed on February 26, 2021 may elect to separately trade the Class A ordinary shares and warrants included in the units commencing on or about April 19, 2021. Any units not separated will continue to trade on the Nasdaq Capital Market under the symbol “SRNGU”, and each of the Class A ordinary shares and warrant..."
03/04/2021 8-K Quarterly results
02/26/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy